ASML has reported robust Q3 2025 financial results, with net sales reaching 7.5 billion euros and a gross margin of 51.6%, surpassing market expectations. Despite the strong performance, the company has cautioned about a potential decline in sales in the Chinese market in 2026, which has led investors to reconsider their positions.
Looking ahead, ASML forecasts Q4 sales to be between 9.2 and 9.8 billion euros, with a gross margin of 52%. Analysts from Morgan Stanley, UBS, and Jefferies have upgraded their ratings on ASML's stock, generally recommending a 'buy' or 'strong buy'. Investors are advised to monitor Q4 revenue outcomes, the upcoming 2026 outlook in January, and developments in Chinese demand.
ASML Reports Strong Q3 Earnings, Warns of 2026 China Sales Decline
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.

